UDG Healthcare plc has today announced the acquisition of Cambridge BioMarketing LLC, a US-based healthcare communications business.
Cambridge BioMarketing is an industry leader in orphan and rare disease drug launches, a fast-growing area of drug development and commercialisation. The orphan drug and rare disease market is forecasted to grow by a CAGR of 11% between 2017 and 2022 to $209bn, with orphan drugs estimated to account for 21.4% of prescription sales by 20221. Cambridge BioMarketing also has a strong creative and digital function in a market where digital content is becoming increasingly important for pharmaceutical companies.
The acquisition of Cambridge BioMarketing provides a platform for growth, specifically in Cambridge, Massachusetts and Oakland, California, both of which have a strong biotech presence. It follows the acquisition of Vynamic, a US-based healthcare industry management consulting firm, announced on 12 July 2017, both of which are in line with Ashfield’s strategy to expand in the US.
Commenting on the announcement, Brendan McAtamney, CEO of UDG Healthcare plc, said: “The acquisition of Cambridge BioMarketing provides us with industry-leading expertise in the fast-growing area of orphan and rare disease drugs and adds further capabilities in patient-focused communications programmes, an increasing focus for pharmaceutical companies. The acquisition is in line with our strategic ambitions to grow our healthcare communications business in the US and expand the range of services we offer to our global pharmaceutical customer base.”
Cambridge BioMarketing CEO, Maureen Franco said: “We are thrilled to be joining UDG Healthcare. Being part of the UDG group provides us with a deeper, complementary suite of services including healthcare communications, consulting, market access, clinical services and meeting and events, as well as a global footprint – allowing us to better serve our clients and providing increased opportunities for our employees.”
For any enquiries please contact Lucy MacLauchlan: Lucy.MacLauchlan@ashfieldhealthcare.com
1Source: Evaluate Pharma Orphan Drug Report 2017